pulmonari
invas
fungal
diseas
ifd
relev
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
establish
risk
factor
rf
ifd
mainli
invas
aspergillosi
ia
includ
factor
associ
profound
immunosuppress
statu
durat
neutropenia
engraft
use
durat
glucocorticosteroid
therapi
type
donor
baselin
diseas
recipi
age
diseas
gvhd
howev
grow
awar
evid
respiratori
viru
carv
also
increas
risk
ia
immunocompromis
healthi
patient
primarili
limit
influenza
recipi
suffer
annual
lifelong
exposur
carv
infect
fact
infect
common
around
obvious
everi
recipi
carv
infect
risk
develop
ifd
date
limit
data
regard
true
rate
ifd
rf
specif
respiratori
viru
infect
critic
period
ifd
develop
carv
infect
recipi
current
studi
come
prospect
longitudin
observ
epidemiolog
survey
carv
infect
complic
recipi
upper
urtd
andor
lower
respiratori
tract
diseas
lrtd
symptom
report
herein
incid
rate
characterist
rf
ifd
seri
consecut
recipi
carv
infect
conduct
prospect
longitudin
studi
carv
infect
adult
year
recipi
two
transplant
center
valencia
hospit
clinic
universitari
valencia
hcuv
hospit
universitari
la
fe
valencia
hlf
spain
cohort
compris
entir
recipi
carv
infect
screen
carv
develop
respiratori
symptom
survey
carri
hcuv
decemb
may
hlf
june
decemb
current
studi
analyz
consecut
carv
infecti
episod
recipi
baselin
diseas
time
carv
detect
decemb
decemb
data
updat
januari
carv
survey
methodolog
previous
describ
detail
briefli
center
develop
prospect
carv
survey
recipi
symptom
suggest
respiratori
viru
infect
irrespect
transplant
date
recipi
urtd
andor
lrtd
symptom
encourag
undergo
detail
respiratori
viru
screen
molecular
test
monitor
viral
shed
neg
first
detect
except
recipi
activ
persist
respiratori
symptom
longer
one
month
case
repeat
pcr
test
rule
acquisit
new
carv
subtyp
carv
found
consid
carv
episod
clinic
biolog
variabl
time
carv
pcr
test
prospect
record
variabl
includ
transplant
characterist
condit
includ
immunodefici
score
index
isi
hospit
admiss
immunosuppress
drug
presenc
acut
chronic
gvhd
use
antifung
prophylaxi
time
carv
infect
subsequ
onset
ifd
recipi
follow
regular
basi
transplant
center
lifelong
studi
protocol
approv
ethic
committe
hospit
universitari
la
fe
refer
code
number
hcuv
januari
februari
antifung
prophylaxi
base
voriconazol
mg
twice
daili
bid
day
day
thereaft
case
activ
gvhd
requir
steroid
therapi
march
antifung
prophylaxi
consist
micafungin
mgday
iv
start
condit
regimen
neutrophil
recoveri
switch
posaconazol
daili
tablet
day
steroid
treat
gvhd
hlf
januari
decemb
antifung
prophylaxi
base
fluconazol
mgday
start
condit
day
stem
cell
infus
day
voriconazol
mgbid
day
thereaft
day
januari
antifung
prophylaxi
chang
consist
fluconazol
mgday
condit
day
posaconazol
mgday
thereaft
day
steroid
urtd
consid
recipi
upper
respiratori
symptom
rhinorrhea
sore
sinus
otiti
pharyng
posit
identif
carv
pcr
test
respiratori
sampl
lack
lrtd
symptom
without
sign
pulmonari
infiltr
chest
ct
scan
classifi
lrtd
possibl
confirm
accord
previou
probabl
episod
sinc
perform
bronchoscopi
patient
without
radiolog
evid
pulmonari
involv
defin
carv
urtd
andor
lrtd
episod
follow
accord
recommend
episod
consid
resolv
complet
remiss
respiratori
symptom
observ
case
new
onset
respiratori
symptom
detect
viru
prior
carv
episod
along
anoth
newli
emerg
carv
consid
new
infecti
diseas
episod
contrast
case
detect
carv
recipi
respiratori
symptom
test
posit
new
emerg
carv
along
initi
carv
consid
uniqu
carv
infecti
diseas
episod
per
protocol
start
oseltamivir
recipi
influenza
infect
provid
respiratori
symptom
resolv
time
microbiolog
result
annual
influenza
vaccin
also
recommend
patient
transplant
center
third
month
follow
patient
gvhd
time
vaccin
program
receiv
gammaglobulin
antithymocyt
globulin
atg
rituximab
within
three
month
flu
vaccin
period
vaccin
administr
remain
physician
respiratori
syncyti
viru
rsv
human
parainfluenza
viru
hpiv
manag
accord
intervent
briefli
oral
ribavirin
given
load
dose
maximum
daili
dose
mgkg
resolut
respiratori
symptom
recipi
lrtd
caus
rsv
hpiv
wherea
patient
urtd
must
isi
point
andor
risk
factor
accord
ecil
andor
present
one
viru
es
start
ribavirin
routin
prophylact
intraven
immunoglobulin
gkg
given
igg
serum
level
mgdl
ifd
diagnosi
classif
perform
agre
definit
european
organ
research
treatment
cancer
mycos
studi
group
eortcmsg
possibl
ifd
episod
consid
final
includ
analys
ifd
date
taken
date
test
yield
diagnosi
ifd
consid
directli
relat
carv
infect
occur
month
follow
either
date
carv
detect
date
recent
carv
detect
case
activ
respiratori
symptom
viral
shed
sever
consecut
pcr
test
detect
carv
recipi
ifd
prior
develop
carv
episod
consid
ifd
includ
analys
acut
diseas
agvhd
defin
accord
standard
carv
test
perform
three
multiplex
platform
two
describ
detail
briefli
luminex
xtag
rvp
fast
assay
luminex
molecular
diagnost
pneumovir
dna
array
assay
genomica
use
hcuv
hlf
respect
hlf
juli
onward
carv
screen
recipi
perform
biofir
respiratori
panel
biofir
diagnost
biomerieux
compani
abl
detect
respiratori
virus
influenza
influ
viru
type
b
c
influenza
subtyp
hpiv
type
adenoviru
adv
coronavirus
hcov
human
metapneumoviru
hmpv
human
rhinovirusenteroviru
evrh
rsv
also
detect
three
bacteria
mycoplasma
pneumonia
chlamydia
pneumonia
bordetella
pertussi
center
aspergillu
galactomannan
antigen
gm
monitor
aspergillu
ag
kit
perform
recipi
gm
monitor
done
serum
sampl
twice
week
day
stem
cell
infus
hospit
discharg
weekli
basi
thereaft
day
outpati
visit
receiv
steroid
treat
gvhd
afterward
gm
also
screen
bronchoalveolar
lavag
fluid
primari
endpoint
current
studi
determin
ifd
incid
rf
recipi
prior
document
carv
urtd
andor
lrtd
secondari
endpoint
includ
analysi
ifd
characterist
effect
overal
surviv
os
categor
variabl
frequenc
compar
use
test
fisher
exact
test
wherea
u
test
use
compar
differ
median
gener
estim
equat
gee
use
assess
associ
clinic
biolog
rf
ifd
method
use
analyz
cluster
data
episod
group
within
patient
gee
fit
margin
mean
model
asymptot
normal
consist
estim
correct
specif
margin
mean
two
differ
model
carri
current
studi
one
evalu
rf
ifd
overal
carv
limit
lower
respiratori
tract
respons
variabl
ifd
factor
follow
atg
part
condit
x
carv
lrtd
x
year
x
corticosteroid
x
patient
cmv
statu
x
moreov
bj
random
effect
associ
individu
j
sij
experiment
error
consid
random
independ
analog
model
associ
lower
respiratori
tract
respons
variabl
ifd
factor
follow
atg
part
condit
x
activ
gvhd
time
rvi
x
year
x
corticosteroid
x
patient
cmv
statu
x
moreov
bj
random
effect
associ
individu
j
sij
experiment
error
consid
random
independ
method
best
model
select
independ
model
criterion
qic
method
propos
theori
gee
typic
model
select
criteria
akaik
inform
criterion
aic
use
gee
base
maximum
likelihood
theori
test
variabl
includ
type
donor
hla
mismatch
atg
part
condit
gvhd
prophylaxi
carv
lrtd
triazol
antifung
prophylaxi
immunosuppress
drug
absolut
lymphocyt
count
alc
alc
alc
absolut
neutrophil
count
age
year
activ
gvhd
time
carv
month
year
myeloabl
condit
corticosteroid
viral
isi
score
low
moder
high
patient
cmv
serostatu
receiv
antivir
therapi
analys
carri
packag
barton
qic
calcul
probabl
os
accord
subsequ
presenc
absenc
ifd
consid
time
carv
detect
use
perform
univari
comparison
descript
surviv
analys
carri
spss
version
statist
packag
one
hundr
recipi
carv
episod
recipi
carv
episod
episod
carv
episod
carv
episod
diagnos
median
day
transplant
rang
day
carv
episod
limit
urtd
wherea
lrtd
involv
possibl
lrtd
proven
lrtd
antivir
therapi
oseltamivir
ribavirin
given
carv
episod
tabl
summar
common
carv
type
rate
urtd
lrtd
recipi
develop
ifd
within
two
month
carv
episod
median
day
rang
day
day
carv
diagnosi
five
case
ifd
diagnos
median
day
rang
day
initi
carv
diagnosi
howev
case
respiratori
symptom
repeat
pcr
test
detect
carv
subtyp
two
month
diagnosi
ifd
ifd
involv
lung
case
diagnost
ia
meet
criteria
probabl
n
proven
n
probabl
ia
case
gm
index
blood
n
andor
bal
n
threshold
valu
remain
patient
develop
proven
pulmonari
invas
fungal
diseas
caus
cladophialopora
carrionii
isol
consecut
bal
cultur
confirm
autopsi
scedosporium
apiospermum
bal
cultur
mucor
racemosu
diagnos
autopsi
patient
clinic
biolog
characterist
accord
whether
develop
ifd
shown
tabl
ifd
group
significantli
higher
rate
factor
includ
isi
score
lymphopenia
activ
gvhd
steroid
therapi
p
comparison
note
ifd
occur
within
first
year
transplant
overal
rate
ifd
carv
wherea
rate
higher
recipi
develop
carv
first
year
transplant
ifd
diagnos
lrtd
episod
compar
urtd
episod
p
carv
episod
involv
lrtd
within
first
year
transplant
develop
ifd
found
differ
ifd
rate
accord
carv
type
tabl
gee
model
rf
ifd
overal
carv
episod
lrtd
shown
tabl
order
identifi
transplant
carv
circumst
relat
ifd
includ
evalu
recipientepisod
pair
gee
model
lower
qic
calcul
includ
variabl
atg
part
condit
carv
lrtd
year
corticosteroid
viral
patient
cmv
serostatu
four
statist
signific
rf
condit
regimen
odd
ratio
confid
interv
ci
p
carv
lrtd
ci
p
carv
infect
first
year
transplant
ci
p
corticosteroid
carv
ci
p
base
rf
elabor
risk
score
group
accord
presenc
rf
figur
risk
model
predict
differenti
group
differ
probabl
develop
later
ifd
analyz
episod
carv
involv
lrtd
determin
rf
ifd
case
n
gee
model
lower
qic
calcul
includ
variabl
atg
part
condit
activ
gvhd
year
viral
patient
cmv
serostatu
three
statist
signific
rf
atg
associ
higher
probabl
ifd
ci
p
carv
lrtd
first
year
transplant
ci
p
final
activ
gvhd
also
associ
ifd
ci
p
develop
ifd
carv
associ
wors
os
three
month
carv
diagnosi
os
carv
episod
develop
ifd
vs
ifd
p
howev
os
recipi
lrtd
develop
ifd
similar
without
ifd
vs
respect
p
figur
b
studi
show
overal
ifd
rate
recipi
wherea
rate
accord
overal
carv
infecti
episod
carv
episod
gee
analysi
identifi
atg
carv
lrtd
carv
episod
within
first
year
transplant
corticosteroid
carv
main
rf
ifd
rf
led
stratif
risk
group
statist
signific
differ
ifd
rate
remark
patient
low
risk
none
rf
low
ifd
rate
although
ifd
rate
still
low
recipi
rf
recipi
rf
show
higher
rate
ifd
addit
found
atg
activ
gvhd
carv
episod
first
year
transplant
main
rf
ifd
recipi
carv
lrtd
although
relationship
carv
invas
mold
infect
andor
ia
consist
establish
true
rate
ifd
recipi
develop
carv
infect
known
data
retrospect
seri
report
rate
ifd
carv
recipi
rang
howev
ifd
rate
vari
accord
carv
locat
urtd
lrtd
time
carv
diagnosi
presenc
concurr
rf
sens
ifd
rate
recipi
urtd
wherea
lrtd
ifd
rate
even
higher
recipi
develop
carv
lrtd
first
year
stem
cell
infus
data
show
ifd
rate
lower
previous
report
one
differ
may
explain
potenti
select
bia
introduc
retrospect
studi
sinc
like
mostli
sever
case
includ
contrast
data
came
prospect
carv
survey
made
possibl
detect
high
number
carv
episod
particular
mild
moder
case
lead
repres
rate
report
herein
note
studi
conduct
set
antifung
prophylaxi
period
higher
risk
first
month
transplant
andor
corticosteroid
therapi
strategi
univers
appli
thu
like
use
triazol
prophylaxi
may
reduc
ifd
rate
current
studi
provid
signific
insight
rf
ifd
particular
scenario
first
observ
ifd
case
occur
first
year
transplant
particularli
recipi
lrtd
import
observ
suggest
prophylact
diagnost
effort
focus
context
current
studi
confirm
carv
lrtd
independ
rf
ifd
point
direct
carv
involv
alter
bronchial
mucosa
pulmonari
defens
fact
ifd
later
event
seri
recipi
develop
ifd
day
might
explain
neutropenia
enter
potenti
rf
gee
model
contrast
use
atg
import
rf
ifd
find
surpris
sinc
atg
produc
lymphopenia
signific
deferr
immun
reconstitut
longer
year
stem
cell
atg
previous
identifi
rf
fact
activ
recogn
signific
regul
activ
pulmonari
inflamm
like
ad
antifung
effector
anoth
potenti
explan
could
atg
seri
mainli
use
context
singl
cbu
transplant
overal
atg
use
procedur
consist
associ
higher
incid
ifd
sourc
hematopoiet
stem
per
protocol
current
seri
recipi
corticosteroid
therapi
receiv
triazol
antifung
prophylaxi
howev
corticosteroid
use
still
associ
increas
risk
ifd
carv
infect
seri
find
complet
unexpect
sinc
well
establish
corticosteroid
increas
risk
ifd
addit
use
corticosteroid
context
carv
infect
recipi
may
favor
carv
progress
urtd
condit
togeth
may
explain
higher
risk
ifd
corticosteroid
use
spite
adequ
antifung
prophylaxi
although
data
support
neg
effect
corticosteroid
therapi
host
immun
respons
may
also
reflect
biolog
influenc
underli
diseas
regard
type
carv
previou
report
focus
attent
influenza
infect
increas
risk
ia
critic
ill
immunosuppress
howev
data
indic
set
carv
except
hcov
hbov
like
facilit
ifd
observ
point
risk
ifd
consid
type
carv
final
develop
invas
pulmonari
ifd
complic
carv
infect
neg
effect
outcom
dismal
prognosi
ifd
well
current
seri
mortal
significantli
higher
recipi
ifd
fact
highlight
need
effect
diagnost
prevent
strategi
detect
reduc
ifd
sever
immunosuppress
patient
acknowledg
studi
limit
use
differ
antifung
prophylaxi
strategi
time
use
three
differ
pcr
method
differ
minim
analyt
perform
spite
studi
strength
merit
consider
notabl
use
molecular
test
data
collect
prospect
carv
survey
conclus
provid
evid
ifd
carv
infect
signific
show
neg
associ
outcom
recipi
rf
may
requir
close
monitor
futur
develop
ifd
jlp
dn
respons
analyz
write
supervis
write
manuscript
mdg
jm
il
ap
eg
emgb
cc
mg
ms
gs
jchb
cs
js
respons
review
analysi
interpret
suggest
modif
text
critic
review
manuscript
final
approv
manuscript
